Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinuvel PharmaceuticalsCUVL -5.14%89 Peter Lynch Fair Value is $11.68 as of Jul. 22, 2026, which is 1012% above its 10-year median of 1.05. GuruFocus rates CUVL with a GF Score™ of 89/100 and a GF Value™ of $12.96 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 67 Biotechnology companies, Clinuvel Pharmaceuticals ranks better than 86.57% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, Clinuvel Pharmaceuticals's PEG is 1. Clinuvel Pharmaceuticals's 5-Year TTM EBITDA Growth Rate is 25.
Clinuvel Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $0.47. Therefore, the Peter Lynch Fair Value for today is $11.68.
The historical rank and industry rank for Clinuvel Pharmaceuticals's Peter Lynch Fair Value or its related term are showing as below:
CUVL'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.53 Med: 1.05 Max: 1.47
Current: 0.53
During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Clinuvel Pharmaceuticals was 1.47. The lowest was 0.53. And the median was 1.05.
CUVL's Price-to-Peter-Lynch-Fair-Value is ranked better than 86.57% of 67
companies
in the Biotechnology industry
Industry Median: 1.2
vs CUVL: 0.53
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
Clinuvel Pharmaceuticals (NAS:CUVL) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 25 instead of 15 in this case.
Clinuvel Pharmaceuticals's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
7.02
/
11.68
=
0.60
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinuvel Pharmaceuticals Peter Lynch Fair Value Related Terms
Clinuvel Pharmaceuticals Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for Clinuvel Pharmaceuticals's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinuvel Pharmaceuticals Peter Lynch Fair Value Chart
CUVL vs VRTX, REGN, ALNY: Peter Lynch Fair Value Comparison
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals Price-to-Peter-Lynch-Fair-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's Price-to-Peter-Lynch-Fair-Value falls into.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clinuvel Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $0.47.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
What does a Peter Lynch Fair Value of $11.68 mean?
Clinuvel Pharmaceuticals (CUVL) has a Peter Lynch Fair Value of $11.68 as of Jul. 22, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Clinuvel Pharmaceuticals and its competitors. This is 1012% above median its historical median of 1.05. Over the past decade, Clinuvel Pharmaceuticals' Peter Lynch Fair Value has ranged from 0.53 to 1.47. According to the industry distribution chart, Clinuvel Pharmaceuticals ranks #9 out of 67 companies in the Biotechnology industry, placing it in the top 13.4%.
Is Clinuvel Pharmaceuticals' Peter Lynch Fair Value too high?
Clinuvel Pharmaceuticals' current Peter Lynch Fair Value of $11.68 is 1012% above median its 10-year median of 1.05. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 1.47. The Biotechnology industry median Peter Lynch Fair Value is 1.20. Clinuvel Pharmaceuticals' value of $11.68 is 873.3% above this industry median. Based on the distribution chart, Clinuvel Pharmaceuticals ranks #9 out of 67 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' Peter Lynch Fair Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clinuvel Pharmaceuticals ranks #9 out of 67 companies for Peter Lynch Fair Value. This places Clinuvel Pharmaceuticals in the top 13% of its industry — outperforming the majority of peers. The industry median Peter Lynch Fair Value is 1.20. Clinuvel Pharmaceuticals' value of $11.68 is 873.3% above this benchmark. Historically, Clinuvel Pharmaceuticals' own Peter Lynch Fair Value has ranged from 0.53 to 1.47 over the past decade. While the company's 10-year median is 1.05 vs. the industry median of 1.20, Clinuvel Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Biotechnology company?
The median Peter Lynch Fair Value among Biotechnology companies is 1.20, based on 67 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinuvel Pharmaceuticals's current Peter Lynch Fair Value of $11.68 is 873.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Clinuvel Pharmaceuticals and its competitors. For the Biotechnology industry, the median Peter Lynch Fair Value is 1.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinuvel Pharmaceuticals's current Peter Lynch Fair Value is $11.68, which is 1012% above median its own 10-year median of 1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (CUVL) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.96, compared to a current price of $7.02 — trading 45.8% below its estimated fair value. The current Peter Lynch Fair Value is $11.68, which is 1012% above median its 10-year median of 1.05 and 873.3% above the Biotechnology industry median of 1.20. Clinuvel Pharmaceuticals' overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (CUVL), the current Peter Lynch Fair Value is $11.68 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (CUVL) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of $7.02 is trading 45.8% below its estimated GF Value™ of $12.96.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for CUVL:
Peter Lynch Fair Value: $11.68 (1012% above median its 10-year median of 1.05)
GF Value™: $12.96 vs. price of $7.02 (45.8% below fair value)
Industry Position: 873.3% above the Biotechnology median (#9 of 67)
No single metric tells the full story. See the CUVL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
89GF Score
Get the complete analysis for CUVL
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CUVL has been successfully added to your 
